Renalytix (Renalytix) Net Change in Cash : $-28.32 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Renalytix Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Renalytix's Net Change in Cash for the three months ended in Mar. 2024 was $-0.91 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was $-28.32 Mil.

Renalytix Net Change in Cash Historical Data

The historical data trend for Renalytix's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renalytix Net Change in Cash Chart

Renalytix Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Net Change in Cash

Get a 7-Day Free Trial

8.12

5.09

51.87

-23.80

-16.65

Renalytix Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Change in Cash	Get a 7-Day Free Trial															9.21	-8.35	-10.79	-8.27	-0.91

Renalytix Net Change in Cash Calculation

Renalytix's Net Change in Cash for the fiscal year that ended in Jun. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-34.085	+	0	+	16.386	+	1.048
	=	-16.65

Renalytix's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -4.938 + 0 + 4.114 + -0.088

= -0.91

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-28.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renalytix Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Renalytix's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Renalytix (Renalytix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (NAS:RNLX) » Definitions » Net Change in Cash

Comparable Companies

LSE:COG LSE:INHC LSE:FDBK LSE:TRLS LSE:IQAI AQSE:DXSP LSE:KOO LSE:INS VEEV GEHC TSE:2413 HQY ASX:PME RCM TXG DOCS PGNY EVH TDOC HKSE:01833

Traded in Other Exchanges

RTNXF:USA RENX:UK 2O9A:Germany 2O9A:Germany 2O9:Germany

Address

5-7 Cranwood Street, Finsgate, London, GBR, EC1V 9EE

Website

https://www.renalytix.com

Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Executives

Howard Jr Doran officer: Chief Business Officer C/O HOLOGIC, INC., 35 CROSBY DRIVE, BEDFORD MA 01730

Daniel J Levangie director 85 SWANSON ROAD, BOXBOROUGH MA 01719

Thomas H Mclain officer: President NABI PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD N.W., BOCA RATON FL 33487

Timothy J Scannell director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002

Catherine Coste director 966 OCHO RIOS DR, DANVILLE CA 94526

Mount Sinai Health System, Inc. 10 percent owner 150 EAST 42ND STREET, SUITE 2-B.17, NEW YORK NY 10017

Icahn School Of Medicine At Mount Sinai 10 percent owner 1 GUSTAVE L. LEVY PLACE, NEW YORK NY 10029

Christopher Mills director, 10 percent owner C/O RENALYTICS PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE

O. James Sterling officer: Chief Financial Officer C/O STAR MOUNTAIN CREDIT OPPS FUND, LP, 140 E. 45TH STREET, 37TH FLOOR, NEW YORK NY 10017

Mount Sinai Hospitals Group, Inc. 10 percent owner ONE GUSTAVE L. LEVY PLACE, NEW YORK NY 10029

Sinai Hospital Mount 10 percent owner ONE GUSTAVE L LEVY PLACE, NEW YORK NY 10029

Fergus Fleming director, officer: Chief Technical Officer C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE

Chirag R. Parikh director C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE

Erik Lium director C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE

James Renwick Mccullough director, officer: Chief Executive Officer C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE

Renalytix (Renalytix) Headlines

From GuruFocus

Renalytix Announces Two Data Presentations on KidneyIntelX� at American Diabetes Association 82nd Scientific Sessions�
By PurpleRose PurpleRose • 07-12-2022

Renalytix to Report Financial Results for First Quarter Fiscal Year 2023 on November 30
By Value_Insider Value_Insider • 11-22-2022

1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX� Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients
By GuruFocusNews GuruFocusNews • 07-10-2022

Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
By sperokesalga sperokesalga • 02-09-2023

Renalytix announces a c.$20.3 million private placement
By Stock market mentor Stock market mentor • 02-08-2023

Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States
By Stock market mentor Stock market mentor • 01-26-2023

Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2022 on October 31
By Value_Insider Value_Insider • 10-24-2022

FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease
By Marketwired • 06-29-2023

Renalytix Completes Agreement with Veterans Administration to Integrate KidneyIntelX Testing across all Electronic Health Record systems
By Stock market mentor Stock market mentor • 01-09-2023

Renalytix Reports Full Year Fiscal 2023 Results
By Marketwired • 09-28-2023

Howard Jr Doran	officer: Chief Business Officer	C/O HOLOGIC, INC., 35 CROSBY DRIVE, BEDFORD MA 01730
Daniel J Levangie	director	85 SWANSON ROAD, BOXBOROUGH MA 01719
Thomas H Mclain	officer: President	NABI PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD N.W., BOCA RATON FL 33487
Timothy J Scannell	director	2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Catherine Coste	director	966 OCHO RIOS DR, DANVILLE CA 94526
Mount Sinai Health System, Inc.	10 percent owner	150 EAST 42ND STREET, SUITE 2-B.17, NEW YORK NY 10017
Icahn School Of Medicine At Mount Sinai	10 percent owner	1 GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Christopher Mills	director, 10 percent owner	C/O RENALYTICS PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
O. James Sterling	officer: Chief Financial Officer	C/O STAR MOUNTAIN CREDIT OPPS FUND, LP, 140 E. 45TH STREET, 37TH FLOOR, NEW YORK NY 10017
Mount Sinai Hospitals Group, Inc.	10 percent owner	ONE GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Sinai Hospital Mount	10 percent owner	ONE GUSTAVE L LEVY PLACE, NEW YORK NY 10029
Fergus Fleming	director, officer: Chief Technical Officer	C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
Chirag R. Parikh	director	C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
Erik Lium	director	C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
James Renwick Mccullough	director, officer: Chief Executive Officer	C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE